drugset / Trial / NCT03396874
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
NaSingle-groupOpen-labelDiagnostic
Summary
This study evaluates the value of Gallium-68 labeled PSMA (68Ga-PSMA) for PET/CT imaging of prostate cancer recurrence. 68Ga-PSMA is a radioactive molecule, which binds to prostate cancer cells. Together with a PET/CT scanner, the distribution of 68Ga-PSMA can be determined in the body. To test this new drug, participants will receive an intravenous injection of Ga-68-PSMA and then have a PET/CT scan. The scan results will be made available to study participants and treating physicians.
Timeline
- Start
- 2018-02-09
- Primary completion
- 2022-08-09
- Completion
- 2022-08-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | 185 mbq | Intravenous |